Sagimet Biosciences SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 22, 2026, 7:15 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedSagimet Biosciences Updates Investor Presentation; First AURORA Phase 3 Patient Dosed, Cash Cited at $257.6 Million
SCHEDULE 13GOct. 7, 2026, 6:28 p.m. ETView on SEC.gov
8-KSept. 30, 2026, 6 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Financial statements and exhibits
424B5Sept. 30, 2026, 5:53 p.m. ETView on SEC.gov
8-KSept. 30, 2026, 6:09 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
4Aug. 17, 2026, 4:05 p.m. ETView on SEC.gov
SCHEDULE 13GAug. 14, 2026, 6:09 a.m. ETView on SEC.gov
8-KAug. 13, 2026, 7:05 a.m. ETView on SEC.gov
Other events
4Aug. 12, 2026, 7:41 p.m. ETView on SEC.gov
8-KAug. 11, 2026, 7:35 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
10-QAug. 11, 2026, 7:30 a.m. ETView on SEC.gov
SCHEDULE 13GJuly 30, 2026, 11:18 a.m. ETView on SEC.gov